| Literature DB >> 21276273 |
Jennifer J Verhoeven1, Marieke den Brinker, Anita C S Hokken-Koelega, Jan A Hazelzet, Koen F M Joosten.
Abstract
INTRODUCTION: The objective of this study was to investigate the occurrence of hyperglycemia and insulin response in critically ill children with meningococcal disease in the intensive care unit of an academic children's hospital.Entities:
Mesh:
Year: 2011 PMID: 21276273 PMCID: PMC3221973 DOI: 10.1186/cc10006
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Patient characteristics on admission
| Shock non-survivors | Shock survivors | Sepsis survivors | |
|---|---|---|---|
| Number | 10 | 57 | 11 |
| Females/Males | 2/8 | 24/33 | 6/5 |
| Age, years | 1.1 (0.6-2.2)a,b | 4.1 (1.8-9.3)c | 6.1 (2.8-11.4)c |
| PRISM score | 31 (25-35)d,e | 21 (16-28)e,f | 9 (8-11)d,f |
| Inotropic medication, number (percentage) | 10 (100%) | 57 (100%) | 2 (18%) |
| Vasopressor score | 3 (3-3) | 2 (1-3) | 0 (0-1) |
| Mechanical ventilation, number (percentage) | 10 (100%) | 37 (65%) | 2 (18%) |
| Steroid treatment, number (percentage) | 2 (20%) | 6 (11%) | 1 (9%) |
| Prednisolone equivalents, mg/kg | 0.9 (0.2-1.6) | 2.4 (0.6-4.5) | 1.0 |
| Glucose intake, mg/kg per minute | 3.3 (0-5.8) | 3.9 (1.4-5.0) | 1.1 (0.6-3.1) |
Data are expressed as median (25th-75th percentile) unless indicated otherwise. The vasopressor score was developed by Hatherill and colleagues [26]. acompared with shock survivors, P < 0.05; bcompared with sepsis survivors, P < 0.05; ccompared with shock non-survivors, P < 0.05; dcompared with shock survivors, P < 0.001; ecompared with sepsis survivors, P < 0.001; fcompared with shock non-survivors, P < 0.001. PRISM, pediatric risk of mortality.
Laboratory parameters on admission and at 24 and 48 hours
| Shock non-survivors | Shock survivors | Sepsis survivors | ||||
|---|---|---|---|---|---|---|
| ( | ( | ( | ( | ( | ( | |
| Glucose, mmol/L | 4.9a,b | 7.2,b,c | 6.7 | 5.9 | 8.8a,c | 6.6 |
| (2.7-7.0) | (5.3-9.0) | (5.9-7.8) | (5.3-6.6) | (7.5-10.5) | (4.7-7.1) | |
| Insulin, pmol/L | <35a,b | 101c | 111 | 89 | 104c | 136 |
| (<35-57) | (35-197) | (71-169) | (61-157) | (52-226) | (51-236) | |
| C-peptide, nmol/L | - | 1.1 | 2.0 | 1.5 | 1.0 | 1.7 |
| (0.6-2.7) | (1.0-3.0) | (1.0-1.9) | (0.5-1.8) | (1.0-2.6) | ||
| Cortisol but not glucocorticoids, nmol/L | 615a,b | 954c | 603 | 554 | 1,140c | 447 |
| (510-930) | (713-1,241) | (430-1,409) | (501-927) | (1,066-1,409) | (263-657) | |
| FFAs, mmol/L | 0.3 | 0.8 | 0.6 | 0.3 | 0.6 | 0.5 |
| (0.2-0.5) | (0.5-1.1) | (0.4-0.8) | (0.3-0.6) | (0.5-0.7) | (0.4-0.7) | |
| Lactate, mmol/L | 6.8d,e | 3.7e,f | 2.0 | 1.6 | 2.1d,f | 0.8 |
| (5.1-8.0) | (2.6-5.4) | (1.5-2.8) | (1.2-2.3) | (1.6-2.7) | (0.7-0.9) | |
| CRP, mg/L | 34a,e | 89c | 229 | 223 | 75f | 236 |
| (23-41) | (59-131) | (181-274) | (159-301) | (36-191) | (195-273) | |
| IL-6, pg/mL | 120 × 104d,f | 3.5 × 104e,f | 0.02 × 104b | 0.01 × 104 | 0.04 × 104d,f | 17a |
| (70-160 × 104) | (1-16 × 104) | (0.01-0.2 × 104) | (0.003-0.03 × 104) | (82-1 × 104) | (<10-0.02 × 104) | |
| TNF-α, pg/mL | 42d | 6f | 4 | - | - | 3 |
| (20-127) | (<5-10.5) | (1-12) | (1-10) | |||
Children who received steroids before or on admission were excluded from determination of median cortisol levels. Data are expressed as median (25th-75th percentile). aCompared with shock survivors, P < 0.05; bcompared with sepsis survivors, P < 0.05; ccompared with shock non-survivors, P < 0.05; dcompared with shock survivors, P < 0.001; ecompared with sepsis survivors, P < 0.001; fcompared with shock non-survivors, P < 0.001; gone patient with insulin therapy was excluded. CRP, C-reactive protein; FFA, free fatty acid; IL-6, interleukin-6; T0, on admission; T24, at 24 hours after admission; T48, at 48 hours after admission; TNF-α, tumor necrosis factor-alpha.
Figure 1Relationship between plasma insulin levels and blood glucose levels on admission in shock non-survivors, shock survivors, and sepsis survivors (.
Figure 2Mean glucose intake rates and insulin levels on admission in shock non-survivors, shock survivors, and sepsis survivors. Bars represent mean insulin levels, and dots represent glucose intake rates. Insulin levels in shock survivors and sepsis survivors were significantly higher than in shock non-survivors (*P < 0.05). There were no differences in glucose intake between the patient categories.
Figure 3Homeostasis model assessment and blood glucose levels on admission in shock non-survivors, shock survivors, and sepsis survivors. (a) Homeostatis model assessment of insulin sensitivity (HOMA-%S). The vertical, x-axis reference line represents the limit for normoglycemia (8.3 mmol/L). The horizontal, y-axis reference line represents 50% of maximum insulin sensitivity. (b) Homeostatis model assessment of β-cell function (HOMA-%B). The vertical, x-axis reference line represents the limit for normoglycemia (8.3 mmol/L). The horizontal, y-axis reference line represents 50% of maximum β-cell function.
Figure 4HOMA-%B plotted against HOMA-%S for hyperglycemic shock non-survivors, shock survivors, and sepsis survivors on admission. HOMA-%B, homeostatis model assessment of β-cell function; HOMA-%S, homeostatis model assessment of insulin sensitivity.